Literature DB >> 19756377

Synthesis, characterization and in vitro anti-tumor activities of novel 9-ethyl-9H-purine derivatives.

Raghu Ningegowda1, Amit Grover, S Ranjith, Kanchugarakoppal S Rangappa, B S Priya, S Nanjunda Swamy.   

Abstract

Newer series of 9-ethyl-9H-purine derivatives (EPD) were synthesized and screened for their efficacy in inhibiting the proliferation of various tumor cells in vitro. We evaluated the effects of EPD against HeLa, SiHa, CaSki (human cervical cancer cells), LM8, LM8G7 (murine osteosarcoma cells), OVSAHO and SKOV-3 (human ovarian cancer cells). The chemical structures of the EPD were confirmed by (1)H NMR and LCMS analyses. The inhibitory effects of EPD were studied by using trypan blue exclusion, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and TetraColor One reagents. Furthermore, SAR studies revealed that the presence of trifluoromethoxy and trifluromethyl group in 4b and 4g, respectively are responsible for the significant activity of the EPD against cervical cancer cells and the presence of isopropoxy group in 4f has influence in inhibiting the proliferation of osteosarcoma and ovarian cancer cell types.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19756377     DOI: 10.1007/s10637-009-9309-6

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  24 in total

1.  Myeloid and monocytoid leukemia cells have different sensitivity to differentiation-inducing activity of deoxyadenosine analogs.

Authors:  N Niitsu; M Umeda; Y Honma
Journal:  Leuk Res       Date:  2000-01       Impact factor: 3.156

2.  Myoseverin, a microtubule-binding molecule with novel cellular effects.

Authors:  G R Rosania; Y T Chang; O Perez; D Sutherlin; H Dong; D J Lockhart; P G Schultz
Journal:  Nat Biotechnol       Date:  2000-03       Impact factor: 54.908

3.  Induction of apoptosis in human papillomaviruspositive cancer cells by peptide aptamers targeting the viral E6 oncoprotein.

Authors:  K Butz; C Denk; A Ullmann; M Scheffner; F Hoppe-Seyler
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

4.  Further evidence on the mode of action of 8-azaguanine (guanazolo) in tumor inhibition.

Authors:  G W KIDDER; V C DEWEY; R E PARKS; G L WOODSIDE
Journal:  Cancer Res       Date:  1951-03       Impact factor: 12.701

5.  Activation of p53 in cervical carcinoma cells by small molecules.

Authors:  S Hietanen; S Lain; E Krausz; C Blattner; D P Lane
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-18       Impact factor: 11.205

6.  Use of the Suzuki reaction for the synthesis of aryl-substituted heterocycles as corticotropin-releasing hormone (CRH) antagonists.

Authors:  A J Cocuzza; D R Chidester; S Culp; L Fitzgerald; P Gilligan
Journal:  Bioorg Med Chem Lett       Date:  1999-04-05       Impact factor: 2.823

7.  Inhibitory effects of ethyl acetate extract of Cordyceps sinensis mycelium on various cancer cells in culture and B16 melanoma in C57BL/6 mice.

Authors:  Jian Yong Wu; Qiao Xia Zhang; Po Hong Leung
Journal:  Phytomedicine       Date:  2006-01-19       Impact factor: 5.340

8.  Mullerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving p130 and p107.

Authors:  Thanh U Barbie; David A Barbie; David T MacLaughlin; Shyamala Maheswaran; Patricia K Donahoe
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-11       Impact factor: 11.205

9.  Human monocytoid leukemia cells are highly sensitive to apoptosis induced by 2'-deoxycoformycin and 2'-deoxyadenosine: association with dATP-dependent activation of caspase-3.

Authors:  N Niitsu; Y Yamaguchi; M Umeda; Y Honma
Journal:  Blood       Date:  1998-11-01       Impact factor: 22.113

10.  Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors.

Authors:  N S Gray; L Wodicka; A M Thunnissen; T C Norman; S Kwon; F H Espinoza; D O Morgan; G Barnes; S LeClerc; L Meijer; S H Kim; D J Lockhart; P G Schultz
Journal:  Science       Date:  1998-07-24       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.